RSV Prevention Implementation Challenges Loom Over Beyfortus’ Regulatory Success

 
• By Bridget Silverman

CDC advisory committee unanimously recommends Sanofi/AstraZeneca’s monoclonal antibody for infants in their first respiratory syncytial virus season and high-risk babies and American Indian children in their second RSV season.

RSV blue sky
• Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers